Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 6, 2025JAC-Antimicrobial ResistanceOpen Access

P04 Low-dose polymyxin B is non-inferior to conventional doses in dialysis dependent and non-dialysis patients with Gram-negative sepsis: a real-world propensity-score matched cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAsha K Rajan

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows lower 28-day mortality in patients treated with low-dose polymyxin B, suggesting benefits in renal replacement therapy.

Key Points

  • Low-dose polymyxin B significantly reduced 28-day mortality among critically ill patients.
  • A hazard ratio of 1.47 indicates usual-dose polymyxin B was tied to higher mortality rates.
  • Observational analysis using propensity score matching accounted for baseline differences across dosing groups.
  • These findings emphasize the potential of lower dosing strategies in patients receiving renal replacement therapy.

Cite This Study

Asha K Rajan (2025) studied this question.

synapsesocial.com/papers/69337d09b3f947a0a125ac68https://doi.org/10.1093/jacamr/dlaf230.011
View Full Paper
Ask AI
Bookmark
Share